Plays a role in promoting resistance to bacterial pathogens such as P.aeruginosa by inhibiting bacterial intestinal colonization. (Microbial infection) Promotes infection by microsporidian pathogens such as N.parisii in the early larval stages of development (PubMed:34994689). Involved in ensuring the proper orientation and location of the spore proteins of N.parisii during intestinal cell invasion (PubMed:34994689). Expressed in the terminal bulb of the pharynx and the posterior of the intestine (at protein level) (PubMed:34994689). Expressed by intestinal cells and secreted into the intestinal lumen (at protein level) (PubMed:34994689). Expressed in the terminal bulb of the pharynx and the posterior of the intestine throughout development (at protein level) (PubMed:34994689). Expressed in the arcade cells of the pharynx in embryos and in L1 stage larvae (at protein level) (PubMed:34994689). Up-regulated following infection by the microsporidian pathogen N.parisii or the bacterial pathogen P.aeruginosa. Resistant to infection by the microsporidian pathogen N.parisii and displays a fitness advantage phenotype, whereby there is increased fitness following infection by N.parisii (PubMed:34994689). Fewer invading N.parisii spores following infection at the L1 larval stage of development due to impaired orientation, location and angle of N.parisii spore proteins relative to the host's intestinal apical membrane (PubMed:34994689). Does not affect the ability of N.parisii to invade intestinal cells or N.parisii spore consumption by intestinal cells of L1 stage larvae (PubMed:34994689). Animals are not resistant to infection by N.parisii at the L3 larval stage of development (PubMed:34994689). Reduced survival following infection by the bacteria P.aeruginosa at the L1 and L4 larval stages due to increased accumulation of the bacteria within the intestinal lumen (PubMed:34994689). Reduced survival and increased numbers of N.parisii spore proteins following co-infection with N.parisii and P.aeruginosa (PubMed:34994689).